Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics